Progression-free survival as a surrogate marker of overall survival

Is it the good question?

Authors

  • Bernard Escudier MD

    Corresponding author
    1. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    • Department of Medical Oncology, Institut Gustave-Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France

    Search for more papers by this author
    • Fax: (011) 33142115211


  • See original referenced article on pages 2637–42, this issue.

Abstract

The use of progression-free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.

Ancillary